Left Ventricular Dysfunction Caused by Combined Pembrolizumab and Lenvatinib Following Doxorubicin
Multidisciplinary discussions are crucial for identifying suspected cardiotoxic chemotherapy and exploring additional chemotherapy options, including rechallenging immune checkpoint inhibitors.
Authors
- Yoshihiko Ikeda
- Masataka Suzuki (ORCID: https://orcid.org/0000-0001-7796-9344)
- Hiromi Hashimura
- E. Konda
- Tsuyoshi Osue (ORCID: https://orcid.org/0000-0002-2328-0821)
- Hiroshi Eizawa
- Yoshihide Ishikawa
Institutions
- National Cerebral and Cardiovascular Center (JP)
- Kobe City Nishi-Kobe Medical Center (JP)
- Kobe University (JP)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.jaccas.2025.104907
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39